ARTICLE | Company News

Anergen other research news

April 11, 1994 7:00 AM UTC

Collaborators of the Redwood City, Calif., company published in vitro data showing that the MG/AnergiX compound selectively induced shut-down of T cell clones obtained from patients with myasthenia gravis (MG).

MG is an autoimmune disease in which autoantibodies are directed against the acetylcholine receptor at the neuromuscular junction. Preincubation with the product, a complex of major histocompatibility complex (MHC) class II peptide and a peptide epitope from the acetylcholine receptor, induced tolerance as well as programmed cell death in the T cells, as reported in the Journal of Clinical Investigation. ...